CAS 880266-57-9|Tanezumab
Introduction：Basic information about CAS 880266-57-9|Tanezumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Tanezumab | ||
|---|---|---|---|
| CAS Number | 880266-57-9 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Tanezumab |
|---|
Tanezumab BiologicalActivity
| Description | Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia[1][2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/ImmunologyResearch Areas >>Neurological Disease |
| Target | NGF[1][2]. |
| References | [1]. Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53. [2]. Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. The Journal of Pain, 2009, 10(4): S44. |
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
